User profiles for Arijit Chakravarty

arijit chakravarty

CEO
Verified email at fractaltx.com
Cited by 1951

MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy

K Hoar, A Chakravarty, C Rabino… - … and cellular biology, 2007 - Am Soc Microbiol
Aurora A kinase plays an essential role in the proper assembly and function of the mitotic
spindle, as its perturbation causes defects in centrosome separation, spindle pole organization…

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

MG Manfredi, JA Ecsedy, A Chakravarty… - Clinical cancer …, 2011 - AACR
Purpose: Small-molecule inhibitors of Aurora A (AAK) and B (ABK) kinases, which play
important roles in mitosis, are currently being pursued in oncology clinical trials. We developed …

[HTML][HTML] Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein

…, M Hixon, D Joseph-McCarthy, A Chakravarty - PloS one, 2021 - journals.plos.org
The spike protein receptor-binding domain (RBD) of SARS-CoV-2 is the molecular target for
many vaccines and antibody-based prophylactics aimed at bringing COVID-19 under control…

SCOPE: a web server for practical de novo motif discovery

JM Carlson, A Chakravarty, CE DeZiel… - Nucleic acids …, 2007 - academic.oup.com
SCOPE is a novel parameter-free method for the de novo identification of potential regulatory
motifs in sets of coordinately regulated genes. The SCOPE algorithm combines the output …

Growth rate analysis and efficient experimental design for tumor xenograft studies: supplementary issue: array platform modeling and analysis (A)

…, WC Shyu, J Donelan, A Chakravarty - Cancer …, 2014 - journals.sagepub.com
Human tumor xenograft studies are the primary means to evaluate the biological activity of
anticancer agents in late-stage preclinical drug discovery. The variability in the growth rate of …

A novel ensemble learning method for de novo computational identification of DNA binding sites

A Chakravarty, JM Carlson, RS Khetani, RH Gross - BMC bioinformatics, 2007 - Springer
Background Despite the diversity of motif representations and search algorithms, the de novo
computational identification of transcription factor binding sites remains constrained by the …

Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics

…, Y Lee, J Ecsedy, V Shinde, A Chakravarty… - Molecular cancer …, 2010 - AACR
This phase I trial examined the safety, pharmacokinetics, and pharmacodynamics of MLN8054,
an oral, selective, small-molecule inhibitor of Aurora A kinase. Patients with advanced …

Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure

…, MS Rogers, D Joseph-McCarthy, A Chakravarty - Scientific reports, 2021 - nature.com
The rapid emergence and expansion of novel SARS-CoV-2 variants threatens our ability to
achieve herd immunity for COVID-19. These novel SARS-CoV-2 variants often harbor …

Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein

…, M Hixon, D Joseph-McCarthy, A Chakravarty - medRxiv, 2020 - medrxiv.org
As many prophylactics targeting SARS-CoV-2 are aimed at the spike protein receptor-binding
domain (RBD), we examined the risk of immune evasion from previously published RBD-…

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase

A Chakravarty, V Shinde, J Tabernero, A Cervantes… - Cancer research, 2011 - AACR
The mitotic kinase Aurora A is an important therapeutic target for cancer therapy. This study
evaluated new mechanism-based pharmacodynamic biomarkers in cancer patients in two …